Literature DB >> 28760498

Differences and similarities between sublingual immunotherapy of allergy and oral tolerance.

Philippe Moingeon1, Laurent Mascarell2.   

Abstract

Allergen immunotherapy is the only treatment altering the natural course of IgE-mediated allergies. Whereas the subcutaneous route for immunotherapy (SCIT) has been historically considered as a reference, we discuss herein the relative advantages of the sublingual and oral routes as alternatives to SCIT in order to elicit allergen-specific tolerance. The buccal and gut immune systems are similarly organized to favor immune tolerance to antigens/allergens, due to the presence of tolerogenic dendritic cells and macrophages promoting the differentiation of CD4+ regulatory T cells. Sublingual immunotherapy (SLIT) is now established as a valid treatment option, with clinical efficacy demonstrated in allergic rhinoconjunctivitis (to either grass, tree, weed pollens or mite allergens) and encouraging results obtained in the management of mild/moderate allergic asthma. While still exploratory, oral immunotherapy (OIT) has shown promising results in the desensitization of patients with food allergies. We review at both biological and clinical levels the perspectives currently pursued for those two mucosal routes.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allergy vaccine; Buccal; Immunotherapy; Oral; Regulatory T cells; Sublingual

Mesh:

Substances:

Year:  2017        PMID: 28760498     DOI: 10.1016/j.smim.2017.07.003

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  1 in total

1.  Human monocyte-derived type 1 and 2 macrophages recognize Ara h 1, a major peanut allergen, by different mechanisms.

Authors:  Maren Krause; Peter Crauwels; Frank Blanco-Pérez; Martin Globisch; Andrea Wangorsch; Thomas Henle; Jonas Lidholm; Ger van Zandbergen; Stefan Vieths; Stephan Scheurer; Masako Toda
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.